Artemova Daria, Vishnyakova Polina, Elchaninov Andrey, Gantsova Elena, Sukhikh Gennady, Fatkhudinov Timur
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution "Petrovsky National Research Centre of Surgery", 3 Tsurupa Street, 117418, Moscow, Russian Federation.
Research Institute of Molecular and Cellular Medicine, RUDN University, 6 Miklukho-Maklaya Street, 117198, Moscow, Russian Federation.
Heliyon. 2024 Aug 14;10(16):e36340. doi: 10.1016/j.heliyon.2024.e36340. eCollection 2024 Aug 30.
Endometriosis is a chronic estrogen-dependent disease characterized by the presence of endometrial glands and stroma outside their normal anatomical location. While laparoscopic removal of foci remains the gold standard therapy, it has limited efficacy and certain risks. However, cell therapy using pro-inflammatory M1 macrophages presents a promising and minimally invasive alternative for treating endometriosis. This approach showcases the potential for innovative and effective treatments for this condition. This study aims to explore the anti-endometriosis properties of M1 macrophages. A reproducible syngeneic mouse model of endometriosis was utilized, revealing that formed foci are primarily composed of macrophages with an anti-inflammatory M2 phenotype rather than M1 macrophages. To investigate further, chemically reprogrammed M1 macrophages were labeled with the membrane fluorescent tag PKH26 and administered to animals with endometriosis. Therapy resulted in a decrease in the number and size of foci, accompanied by a shift in the phenotypic composition of peritoneal macrophages. Specifically, the content of M2 macrophages decreased while that of M1 macrophages increased, resembling the composition of healthy animals. Our study conclusively demonstrates the anti-endometriosis properties of M1 macrophages, providing a strong foundation for future research in the cell therapy of endometriosis.
子宫内膜异位症是一种慢性雌激素依赖性疾病，其特征是子宫内膜腺体和间质出现在正常解剖位置之外。虽然腹腔镜下切除病灶仍然是金标准治疗方法，但其疗效有限且存在一定风险。然而，使用促炎性M1巨噬细胞的细胞疗法为治疗子宫内膜异位症提供了一种有前景的微创替代方案。这种方法展示了针对这种疾病进行创新和有效治疗的潜力。本研究旨在探索M1巨噬细胞的抗子宫内膜异位症特性。利用一种可重复的同基因小鼠子宫内膜异位症模型，发现形成的病灶主要由具有抗炎M2表型的巨噬细胞而非M1巨噬细胞组成。为了进一步研究，用膜荧光标记PKH26标记化学重编程的M1巨噬细胞，并将其给予患有子宫内膜异位症的动物。治疗导致病灶数量和大小减少，同时腹膜巨噬细胞的表型组成发生变化。具体而言，M2巨噬细胞的含量减少，而M1巨噬细胞的含量增加，类似于健康动物的组成。我们的研究最终证明了M1巨噬细胞的抗子宫内膜异位症特性，为未来子宫内膜异位症细胞治疗的研究奠定了坚实基础。
